Comparison of Patent Ductus Arteriosus Stent and Blalock-Taussig Shunt as Palliation for Neonates with Sole Source Ductal-Dependent Pulmonary Blood Flow: Results from the Congenital Catheterization Research Collaborative

Pediatr Cardiol. 2022 Jan;43(1):121-131. doi: 10.1007/s00246-021-02699-7. Epub 2021 Sep 15.

Abstract

Patent ductus arteriosus (PDA) stenting is an accepted method for securing pulmonary blood flow in cyanotic neonates. In neonates with pulmonary atresia and single source ductal-dependent pulmonary blood flow (SSPBF), PDA stenting remains controversial. We sought to evaluate outcomes in neonates with SSPBF, comparing PDA stenting and surgical Blalock-Taussig shunt (BTS). Neonates with SSPBF who underwent PDA stenting or BTS at the four centers of the Congenital Catheterization Research Collaborative from January 2008 to December 2015 were retrospectively reviewed. Reintervention on the BTS or PDA stent prior to planned surgical repair served as the primary endpoint. Additional analyses of peri-procedural complications, interventions, and pulmonary artery growth were performed. A propensity score was utilized to adjust for differences in factors. Thirty-five patients with PDA stents and 156 patients with BTS were included. The cohorts had similar baseline characteristics, procedural complications, and mortality. Interstage reintervention rates were higher in the PDA stent cohort (48.6% vs. 15.4%, p < 0.001).

Keywords: PDA stent; Pulmonary artery; Pulmonary atresia.

MeSH terms

  • Blalock-Taussig Procedure*
  • Cardiac Catheterization
  • Ductus Arteriosus* / surgery
  • Ductus Arteriosus, Patent* / surgery
  • Humans
  • Infant, Newborn
  • Pulmonary Artery / surgery
  • Pulmonary Circulation
  • Retrospective Studies
  • Stents
  • Treatment Outcome